Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: A summary based on 434 patients

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Zhang, Yaoyao ^a   Xiao, Zhun ^a   Wang, Yan ^a   Luo, Shan ^a   Li, Xiaohong ^a   Li, Shangwei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSERELIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FOLLITROPIN; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; MUELLERIAN INHIBITING FACTOR; PREDNISONE; PROCARBAZINE; TRIPTORELIN; VINBLASTINE; VINCRISTINE SULFATE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FEMALE FERTILITY; FOLLITROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; LYMPHOMA; META ANALYSIS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY FUNCTION; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

ADULT; ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LYMPHOMA; PREGNANCY; PREMENOPAUSE; PRIMARY OVARIAN INSUFFICIENCY; REPRODUCTION; TREATMENT OUTCOME;

EID: 84896704915     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080444     Document Type: Article

References (23)

1. Maltaris T, Seufert R, Fischl F, Schaffrath M, Pollow K et al. (2007) The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol 130: 148-155. doi:10.1016/j.ejogrb. 2006.08.006. PubMed: 16979280. (Pubitemid 46097248)
2. Lunardi FO, Araújo VR, Bernuci MP, Lunardi LO, Gonçalves RF et al. (2013) Restoring fertility after ovarian tissue cryopreservation: a half century of research. Zygote, 21: 1-12. PubMed: 23174125.
3. Seli E, Tangir J (2005) Fertility preservation options for female patients with malignancies. Curr Opin Obstet Gynecol 17: 299-308. doi:10.1097/01.gco.0000169108.15623.34. PubMed: 15870565. (Pubitemid 40705041)
4. Salama M, Winkler K, Murach KF, Seeber B, Ziehr SC et al. (2013) Female fertility loss and preservation: threats and opportunities. Ann Oncol 24: 598-608. doi:10.1093/annonc/mds514. PubMed: 23129121.
5. Stern CJ, Toledo MG, Gook DA, Seymour JF (2006) Fertility preservation in female oncology patients. Aust N Z J Obstet Gynaecol 46: 15-23. doi:10.1111/j.1479-828X.2006.00507.x. PubMed: 16441687.
6. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N et al. (2011) Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306: 269-276. doi:10.1001/jama.2011.991. PubMed: 21771987.
7. Demeestere I, Brice P, Peccatori FA, Kentos A, Gaillard I et al. (2013) Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 31: 903-909. doi:10.1200/JCO.2012.42.8185. PubMed: 23129737.
8. Nitzschke M, Raddatz J, Bohlmann MK, Stute P, Strowitzki T et al. (2010) GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin's lymphoma patients. Arch Gynecol Obstet 282: 83-88. doi:10.1007/s00404-009-1308-5. PubMed: 19967405.
9. Castelo-Branco C, Nomdedeu B, Camus A, Mercadal S, Martínez de Osaba MJ et al. (2007) Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril 87: 702-705. doi:10.1016/j.fertnstert.2006.10.004. PubMed: 17173900. (Pubitemid 46385982)
10. Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe JM et al. (2008) Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 89: 166-173. doi:10.1016/j.fertnstert.2007.02. 010. PubMed: 17601603.
11. Huser M, Crha I, Ventruba P, Hudecek R, Zakova J et al. (2008) Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Hum Reprod 23: 863-868. doi:10.1093/humrep/den005. PubMed: 18258763.
12. Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L et al. (2007) Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 12: 141-147. doi:10.1080/10245330600954072. PubMed: 17454195. (Pubitemid 46605523)
13. Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W et al. (1987) Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 19: 159-162. PubMed: 3105906. (Pubitemid 17059373)
14. Moher D, Pham B, Jones A, Cook DJ, Jadad AR et al. (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352: 609-613. doi:10.1016/S0140-6736(98)01085-X. PubMed: 9746022. (Pubitemid 28380142)
15. Shelling AN (2010) Premature ovarian failure. Reproduction 140: 633-641. doi:10.1530/REP-09-0567. PubMed: 20716613.
16. Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C et al. (2010) Anti-Mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online 20: 280-285. doi:10.1016/j.rbmo.2009.11.010. PubMed: 20113967.
17. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M et al. (2012) Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 30: 533-538. doi:10.1200/JCO.2011.34.6890. PubMed: 22231041.
18. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R et al. (2011) Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 29: 2334-2341. doi:10.1200/JCO.2010.32.5704. PubMed: 21537042.
19. Badawy A, Elnashar A, El-Ashry M, Shahat M (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91: 694-697. doi:10.1016/j. fertnstert.2007.12.044. PubMed: 18675959.
20. Bedaiwy MA, Abou-Setta AM, Desai N, Hurd W, Starks D, et al. (2011) Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 95: 906-914 e901-904
21. Chen H, Li J, Cui T, Hu L (2011) Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev: CD: 008018. PubMed: 22071842.
22. Yang B, Shi W, Yang J, Liu H, Zhao H et al. (2013) Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. Breast 22: 150-157. doi:10.1016/j.breast.2012.12.008. PubMed: 23298851.
23. Edmonds DK (1996) Add-back therapy in the treatment of endometriosis: the European experience. Br J Obstet Gynaecol 103 Suppl 14: 10-13. PubMed: 8916980.